Vetoquinol's Forcyl Now Indicated For Acute E.coli Mastitis

Vetoquinol UK is pleased to announce that Forcyl®, the only patented 16% marbofloxacin formulation, is now indicated for the intravenous treatment of acute E.coli mastitis as a Single Injection Short Acting AntiBiotic (SiSAAB). The SiSAAB concept is based on increasing the dose for quick and highly concentrated bactericidal effect, whilst reducing the treatment duration to a single administration to minimise the risk of resistance development. Forcyl is an innovative formulation with a lower volume of administration and an improved injection site tolerance. Forcyl is a highly effective treatment choice for E.coli mastitis with a fast clinical improvement and an optimal return to milk production. The recommended dose rate is a single injection, of 10mg/kg bodyweight i.e. 10ml/160kg. ‘The new indication enables the SiSAAB concept to be demonstrated effectively in E.coli mastitis situations where speed of action and cure rates are essential. The SiSAAB concept minimises the opportunity for resistance to develop, enabling vets to promote the responsible use of antimicrobials as Forcyl enters the mutant selection window (MSW) for a very short period of time’, comments Susan Nash, Senior Product Manager.

More from

• Vetsure Named Business of the Year at 2025 SME National Business Awards
• Home of hope for Romania's dogs: The pioneering shelter doing things differently
• Pioneering new locum platform transforming veterinary landscape
• Key Stakeholders unite to advance helmet design for equine veterinary professionals
• Hallmarq hails transformational equine imaging technology